Temasek Holdings Private Ltd Acquires 1,657,142 Shares of Denali Therapeutics Inc. $DNLI

Temasek Holdings Private Ltd raised its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI) by 30.9% in the 4th quarter, HoldingsChannel reports. The firm owned 7,012,974 shares of the company’s stock after purchasing an additional 1,657,142 shares during the quarter. Temasek Holdings Private Ltd’s holdings in Denali Therapeutics were worth $115,784,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of the business. State of Wyoming raised its position in Denali Therapeutics by 24.7% in the 4th quarter. State of Wyoming now owns 2,686 shares of the company’s stock valued at $44,000 after purchasing an additional 532 shares during the last quarter. Intrust Bank NA raised its position in shares of Denali Therapeutics by 5.6% during the fourth quarter. Intrust Bank NA now owns 11,164 shares of the company’s stock worth $184,000 after acquiring an additional 589 shares during the last quarter. Pier 88 Investment Partners LLC raised its position in shares of Denali Therapeutics by 1.1% during the fourth quarter. Pier 88 Investment Partners LLC now owns 68,200 shares of the company’s stock worth $1,126,000 after acquiring an additional 760 shares during the last quarter. Tudor Investment Corp ET AL raised its position in shares of Denali Therapeutics by 1.7% during the third quarter. Tudor Investment Corp ET AL now owns 56,368 shares of the company’s stock worth $818,000 after acquiring an additional 920 shares during the last quarter. Finally, Assetmark Inc. raised its position in shares of Denali Therapeutics by 31.8% during the fourth quarter. Assetmark Inc. now owns 5,187 shares of the company’s stock worth $86,000 after acquiring an additional 1,250 shares during the last quarter. Institutional investors own 92.92% of the company’s stock.

Denali Therapeutics Stock Up 2.6%

Shares of Denali Therapeutics stock opened at $22.22 on Tuesday. The company has a quick ratio of 9.28, a current ratio of 9.28 and a debt-to-equity ratio of 0.01. Denali Therapeutics Inc. has a 12 month low of $12.58 and a 12 month high of $23.77. The business has a fifty day simple moving average of $19.83 and a 200 day simple moving average of $19.47. The stock has a market cap of $3.53 billion, a PE ratio of -7.72 and a beta of 1.03.

Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.69) EPS for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.04. During the same period last year, the firm earned ($0.78) EPS. Research analysts predict that Denali Therapeutics Inc. will post -2.77 EPS for the current year.

Wall Street Analyst Weigh In

DNLI has been the subject of a number of recent research reports. Leerink Partners dropped their target price on Denali Therapeutics from $40.00 to $35.00 and set an “outperform” rating for the company in a research report on Wednesday, April 22nd. The Goldman Sachs Group boosted their target price on Denali Therapeutics from $35.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday, March 26th. Weiss Ratings restated a “sell (d-)” rating on shares of Denali Therapeutics in a research report on Monday, April 20th. Morgan Stanley decreased their price objective on Denali Therapeutics from $40.00 to $35.00 and set an “overweight” rating for the company in a research note on Friday, May 22nd. Finally, Wolfe Research began coverage on Denali Therapeutics in a research note on Monday, February 23rd. They set a “peer perform” rating for the company. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $34.25.

Denali Therapeutics Company Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.